 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...8788899091929394959697...123124» |
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal, Real-world evidence: Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. (Pubmed Central) - Mar 16, 2021
Incidence of grade 3 or higher toxicity was 35%. In our small, real-world cohort of patients receiving immunotherapy as front-line systemic treatment for HCC, outcomes were poor with front-line immunotherapy.
- | lenvatinib / Generic mfg.
Journal: Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. (Pubmed Central) - Mar 16, 2021
The median progression-free survival was 8.8 months in the HPL group and 5.4 months in the PL group (p = 0.0320; HR = 0.74; 95% CI 0.55-0.98). Compared to PL, HPL was associated with a significantly better treatment response and survival benefits for patients with advanced HCC.
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical: Is there a role for combination #pembrolizumab and #lenvatinib for anaplastic and poorly differentiated #thyroidcancers? @ASCO @ITOGinfo @AmericanCancer https://t.co/XS2cEvp2we #AmericanThyroidAssociation #ClinicalThyroidology #ATAthyroid2021 #endotwitter #medtwitter (Twitter) - Mar 15, 2021
- ||| Nexavar (sorafenib) / Bayer, Amgen
.@docamitgs, of @UTSWNews, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma #hpbcsm https://t.co/nmtQNaFUQo (Twitter) - Mar 14, 2021
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus
[VIRTUAL] A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC) () - Mar 13, 2021 - Abstract #AACR2021AACR_4087;
P1/2
PD-1 inhibition with toripalimab or toripalimab plus multikinase inhibition with lenvatinib result in promising antitumor activity as preoperative therapy in resectable HCC. There were no new or unexpected toxicities resulting from combination.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. (Pubmed Central) - Mar 13, 2021
However, long-term colony formation assay indicated that RRM2 overexpression partially rescues HCC cells from the cytotoxicity of sorafenib. Therefore, this study identifies that RRM2 is a novel target of sorafenib, partially contributing to its anticancer activity in HCC cells.
- || Stivarga (regorafenib) / Bayer, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Mar 13, 2021
Therefore, this study identifies that RRM2 is a novel target of sorafenib, partially contributing to its anticancer activity in HCC cells. No abstract available
- || lenvatinib / Generic mfg.
Clinical, Journal, Real-World Evidence: Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. (Pubmed Central) - Mar 13, 2021
Lenvatinib therapy showed a favorable efficacy and safety in a real-world practice. The REFLECT eligibility criteria and specific AEs could be one of the prognostic markers.
- lenvatinib / Generic mfg.
[VIRTUAL] Patient Education and Management of Adverse Reactions in Patients With Unresectable Hepatocellular Carcinoma (uHCC) Treated With Lenvatinib: Nurse Practitioners Perspective () - Mar 12, 2021 - Abstract #ONS2021ONS_84;
Additionally, monitoring for liver-disease progression, in combination with AE management, is critical in terms of patient safety, lenvatinib adherence, and quality of life. We report the critical role of NPs in educating patients regarding AEs associated with lenvatinib and provide our strategies for managing challenging AEs to maximize patient benefit.
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: New Treatments Emerge for RCC. (Pubmed Central) - Mar 12, 2021
In one, the combination of lenvatinib and pembrolizumab was superior to sunitinib and to lenvatinib plus everolimus in clear-cell RCC. In the other, cabozantinib was more effective than sunitinib in papillary RCC.
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. (Pubmed Central) - Mar 12, 2021
Despite the impressive results and generally good toxicity profile of immunotherapy, patients who respond to therapy constitute only a subset of the overall population, and response rates are still limited. This review focuses on the currently reported results and ongoing clinical trials of checkpoint inhibitor-based immunotherapy in HCC.
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Review, Journal: Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease. (Pubmed Central) - Mar 12, 2021
In addition to sorafenib, lenvatinib and combination atezolizumab-bevacizumab now represent standard first-line treatment options...Furthermore, sequencing of the agents will have to be carefully tailored, given the increasing armamentarium of choices. Here, we discuss the role of lenvatinib and sorafenib in the first-line management of HCC.
- || Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Review, Journal: Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond. (Pubmed Central) - Mar 12, 2021
Similarly, in the post-sorafenib setting, a number of recent positive clinical trials have been reported, and they indicate that regorafenib, cabozantinib, and ramucirumab are effective and safe in the second-line setting...In the present review, we introduce the current data for second-line systemic treatment and beyond in HCC. A treatment algorithm is also suggested, based on the best available evidence and expert opinion.
- bintrafusp alfa (M7824) / GSK, EMD Serono, Merck (MSD)
[VIRTUAL] Bintrafusp alfa enhances the antitumor efficacy of anti-VEGF and VEGF receptor kinase inhibitors in preclinical solid tumor models () - Mar 11, 2021 - Abstract #AACR2021AACR_3404;
Additionally, the combination of bintrafusp alfa with pazopanib also showed superior antitumor efficacy in an orthotopic Renca mouse tumor model. These data indicate that bintrafusp alfa may be a viable combination partner with multiple angiogenesis inhibitors and provide a rational for the continued development of these combination therapies to treat solid cancers.
- favezelimab (MK-4280) / Merck (MSD), MK-4830 / Merck (MSD), belzutifan (MK-6482) / Merck (MSD)
[VIRTUAL] A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors () - Mar 11, 2021 - Abstract #AACR2021AACR_3177;
P1b/2
Primary end points for safety lead-in phase (if applicable) are safety and tolerability to establish an RP2D; co-primary end points for efficacy phase are safety and objective response rate per RECIST v1.1 by blinded independent central review (BICR). Secondary end points during the efficacy phase are duration of response, progression-free survival, and clinical benefit rate per RECIST v1.1 (BICR), and overall survival.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Lenvatinib induces apoptosis and inhibits metastasis through downregulate Wnt/GSK3β/NF-κB in hepatocellular carcinoma () - Mar 11, 2021 - Abstract #AACR2021AACR_2060;
Tumor growth inhibition was also found in lenvatinib treatment group. In conclusion, lenvatinib induces apoptosis and suppresses metastasis was associated with Wnt/GSK3β/NF-κB inactivation.
- Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Analysis of efficacy of receptor tyrosine kinase and immune checkpoint inhibitors and insights to potential combinatorial treatment strategies in cholangiocarcinomas () - Mar 11, 2021 - Abstract #AACR2021AACR_2040;
The combination use of lenvatinib with other TKIs has limited survival benefit. However, it has a trend of giving some additional benefit when in combination with anti-PD-1/L1 therapies.
- eribulin mesylate (E7386) / Eisai, PRISM Pharma
[VIRTUAL] E7386, a CREB binding protein (CBP)/β-catenin interaction inhibitor, suppresses the hypoxic response induced by angiogenesis inhibition in hepatocellular carcinoma models () - Mar 11, 2021 - Abstract #AACR2021AACR_1035;
These results suggest that E7386 enhances angiogenesis inhibition when used in combination with lenvatinib and that E7386 suppresses the hypoxic response induced by angiogenesis inhibition. Further analysis is required to clarify the precise mechanisms of actions of the combination of E7386 plus lenvatinib.
- lenvatinib / Generic mfg.
[VIRTUAL] The safety and efficacy of lenvatinib in preventing early recurrence after liver transplantation for hepatocellular carcinoma beyond Milan criteria: A single-center, retrospective, propensity-matched study () - Mar 11, 2021 - Abstract #AACR2021AACR_382;
Further analysis is required to clarify the precise mechanisms of actions of the combination of E7386 plus lenvatinib. Post-LTx lenvatinib could serve as a safety and effective therapy to reduce tumor recurrence after LTx in HCC patients beyond Milan criteria.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Hyperprogression in follicular thyroid cancer treated with combination immunotherapy () - Mar 11, 2021 - Abstract #AACR2021AACR_368;
The underlying mechanism of hyperprogression and its association with immunotherapy remains unclear. Further research on potential risks of hyperprogression in less immunogenic cancer such as thyroid cancer is warranted.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Serum ST6GAL1 is a novel biomarker for predicting efficacy of tyrosine kinase inhibitors in hepatocellular carcinoma by detecting FGF19 expressing tumor () - Mar 11, 2021 - Abstract #AACR2021AACR_298;
Tumor-bearing mice were then treated with lenvatinib (LEN), or sorafenib (SOR), or vehicle until moribund. ST6GAL1 is a tumor-derived secreted protein downstream of FGF19 and may be a useful serum biomarker for identification of patients with FGF19-driven HCC who may benefit from LEN therapy.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC (clinicaltrials.gov) - Mar 9, 2021
P2, N=64, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- |||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical: .@montypal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma. | @cityofhope https://t.co/j9YZahvgVU (Twitter) - Mar 9, 2021
- || lenvatinib / Generic mfg.
Clinical, Journal: Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas. (Pubmed Central) - Mar 9, 2021
We speculate that lenvatinib quickly blocks the feeding circulation, resulting in tumor hemorrhage by necrosis. Clinicians should pay careful attention to the development of life-threatening hemorrhages when treating large HCCs with lenvatinib.
- || lenvatinib / Generic mfg.
Clinical, Journal: Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. (Pubmed Central) - Mar 9, 2021
18F-FDG-PET/CT has potential as an evaluation tool for describing biological tumor behavior and reflecting disease progression, location, and treatment response. This modality may provide useful information for considering prognosis and subsequent therapy.
- ||| lenvatinib / Generic mfg.
Pricing: In India Lenvatinib cost. 10mg. $1 per caps 4mg. $0.5 per caps (Twitter) - Mar 7, 2021
- | lenvatinib / Generic mfg.
Preclinical, Journal: Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models. (Pubmed Central) - Mar 7, 2021
Furthermore, the combination does not have significant adverse effects in the ATC mouse models in terms of body weight, blood biochemical parameters, and histopathology. In conclusion, the combination of lenvatinib with an MEK inhibitor is a potentially viable therapeutic approach for ATC treatment.
- |||| Mekinist (trametinib) / Novartis
Clinical: Very interesting. We would give lenvatinib for fgfr2 (start at 10 mg daily) and trametinib for Hras (start at 1 mg po daily). Titrate to tolerance. We have given this combo to many patients. Manuscript in the works. Hope this helps (Twitter) - Mar 6, 2021
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 4, 2021
P2, N=50, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 3, 2021
P2, N=47, Not yet recruiting, Sponsor: Floor Backes
- || belzutifan (MK-6482) / Merck (MSD)
Lenvatinib + everolimus followed by belzutifan when available. Tivozinib may soon be an option too @montypal @TiansterZhang @DrVaishampayan (Twitter) - Mar 3, 2021
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Mar 3, 2021
P2, N=32, Active, not recruiting, Sponsor: Virginia G. Kaklamani
In conclusion, the combination of lenvatinib with an MEK inhibitor is a potentially viable therapeutic approach for ATC treatment. Trial completion date: Dec 2020 --> Nov 2021
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date: PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov) - Mar 3, 2021
P2, N=36, Recruiting, Sponsor: The Netherlands Cancer Institute
Trial completion date: Dec 2020 --> Nov 2021 Not yet recruiting --> Recruiting | Trial completion date: Feb 2021 --> Aug 2021 | Trial primary completion date: Feb 2021 --> Aug 2021
- lenvatinib / Generic mfg.
[VIRTUAL] Consideration on the timing of Lenvatinib introduction for patients with unresectable, or recurrent thyroid cancer () - Mar 2, 2021 - Abstract #JSMO2021JSMO_1323;
- lenvatinib / Generic mfg.
[VIRTUAL] Can lenvatinib be used safely in patients with low renal function? Analysis of thyroid cancer patients () - Mar 2, 2021 - Abstract #JSMO2021JSMO_1288;
- lenvatinib / Generic mfg.
[VIRTUAL] Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer (Track 13) - Mar 2, 2021 - Abstract #JSMO2021JSMO_589;
- lenvatinib / Generic mfg.
[VIRTUAL] Impact of baseline tumor size on overall survival in patients with RR-DTC treated with lenvatinib [SELECT] (Track 5) - Mar 2, 2021 - Abstract #JSMO2021JSMO_316;
- lenvatinib / Generic mfg.
[VIRTUAL] Tumor FGFR4 Level Predicts the Efficacy of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma (Track 11) - Mar 2, 2021 - Abstract #JSMO2021JSMO_277;
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
[VIRTUAL] Regorafenib plus Nivolumab or Lenvatinib plus Pembrolizumab for Gastric Cancer (Track 3) - Mar 2, 2021 - Abstract #JSMO2021JSMO_211;
- || lenvatinib / Generic mfg.
Clinical, Observational data, P4 data, Journal: Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan. (Pubmed Central) - Mar 2, 2021
Lenvatinib demonstrated an acceptable safety profile for patients with thyroid cancer in a real-world setting in Japan. The safety profile and effectiveness findings for lenvatinib in this study were consistent with those from previous clinical trials, irrespective of histological subtype.
- || oxaliplatin / Generic mfg., lenvatinib / Generic mfg.
Clinical, Journal: Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis. (Pubmed Central) - Mar 2, 2021
Drug-resistant and metastatic colon cancer cells evaded the anticancer drug effects via angiogenesis. These findings present a breakthrough strategy for treating drug-resistant cancer.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment. (Pubmed Central) - Mar 2, 2021
The objective response rate (ORR) of lenvatinib was 34.8% in the overall patients and 46.7% in the intermediate-stage HCC patients, which was significantly higher than sorafenib (P=0.001, P=0.017). The emergence of lenvatinib has encouraged physicians to start systemic chemotherapy earlier in intermediatestage HCC patients.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) (clinicaltrials.gov) - Mar 2, 2021
P3, N=726, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
The emergence of lenvatinib has encouraged physicians to start systemic chemotherapy earlier in intermediatestage HCC patients. Recruiting --> Active, not recruiting
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Enrollment change, Tumor mutational burden, Metastases: Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 2, 2021
P2, N=36, Recruiting, Sponsor: Baocai Xing
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | N=56 --> 36
- | reozalimab (IBI318) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. (clinicaltrials.gov) - Mar 1, 2021
P2, N=30, Recruiting, Sponsor: Hunan Province Tumor Hospital
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov) - Feb 28, 2021
P3, N=434, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - Feb 26, 2021
P1/2, N=117, Active, not recruiting, Sponsor: Eisai Limited
Not yet recruiting --> Recruiting | N=56 --> 36 Trial completion date: Dec 2020 --> Mar 2022
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Dr. Thomas E. Hutson on results of phase 3 CLEAR trial of pembrolizumab/lenvatinib in RCC https://t.co/OkkXg8dlxT #kcsm #kidneycancer #urology #urologist @DrTHut (Twitter) - Feb 25, 2021
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Get Dr. @shilpaonc’s perspective on Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) (Abstract #269), from LARVOL’s Oncology Panel: ASCO GU. Visit https://t.co/JVOj4w0A9x for the full discussion. #GU21 #ASCOGU #DrugTrial #OncologyPanel (Twitter) - Feb 25, 2021
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer (clinicaltrials.gov) - Feb 25, 2021
P1, N=26, Active, not recruiting, Sponsor: Floor Backes
Trial completion date: Dec 2020 --> Mar 2022 Trial completion date: Nov 2019 --> Dec 2022 | Trial primary completion date: Nov 2019 --> Dec 2021